药品市场调査评论：2011年 是由出版商BCC Research在2012年01月所出版的。
这份英文市场调查报告书包含194 Pages 价格从美金850起跳。
本报告书焦点在今后预估将会大幅发展的药品产业、BCC Research对于2011年报告书中所提及的来自海洋的药品、新兴地区药剂市场、血脑屏障治疗药、精神疾病治疗药、副厂药品、疫苗、临床实验商务领域之科学研究、用途开发以及市场等的动向做重新审视，能明确掌握该产业全体世界性概况与各自的将来性之数値数据整理，述如下。
第1章 2011 药品市场调査评论 ― 前言
第2章 来自海洋得药品之全球市场（PHM101A）
- 导论
- 总纲
- 投资与前途
- 主要推进要因
- 主要课题
- 重要动向
- 投资环境
- 概要
第3章 治疗药的新兴地区市场（PHM076A）
- 导论
- 摘要
- 概要
- 表5：新兴国家2008年经济统计数値与国内总生产
第4章 血脑屏障（BBB：BLOOD-BRAIN BARRIER）技术与世界市场（PHM075A）
- 导论
- 总纲
- 逐渐抬头的血脑屏障技术市场
- 主要推进要因
- 主要课题
- 重要动向
- 概要
- 今日的药剂市场
- 生物制剂
- 宣告技术革新需求的副厂药品
- 制药产业中的重视神经学的态度
- 抬头了的血脑屏障技术市场
- 血脑屏障技术概略史
- 定义血脑屏障
- 构成血脑屏障的器官
- 解说血脑屏障
- 脑的主要领域
- 疾病治疗与血脑屏障
- 血脑屏障治疗技术分类
- 极一般性的血脑屏障技术
- 输送问题
- 详细解说血脑屏障技术
- 强化生体输送系统技法
- 奈米粒子与脂质体
第5章 精神疾病治疗药：技术以及世界市场（PHM074A）
- 导论
- 摘要
- 导论
- 精神卫生药市场的推进要因与课题
- 精神卫生机关
- 精神卫生药市场概要
- 精神病的诊断
- 对于精神疾病的心理疗法
第6章 副厂药品：世界市场（PHM009F）
- 导论
- 摘要
- 市场规模以及进化
- 概要
- 副厂药品领域近年历史
- 副厂新时代
- 濒临消灭的专利
- 副厂药品种类
第7章 疫苗：技术以及世界市场（PHM014D）
第8章 临床实验商务（PHM027C）
- 导论
- 摘要
- 概要
- 临床实验种类
- 临床实验阶段
- 临床实验赞助者
- 第1阶段
- 第2阶段
- 第3阶段
- 第4阶段 - 发售后临床实验
- 对研究规模的影响因子
- 医师与受验者的选定
- 美国政府法规
图表一覧
Abstract
REPORT HIGHLIGHTS
The global market for marine-derived drugs by type was around $4.8 billion in
2011, which is expected to be around $5.3 billion in 2012. This global market
is forecasted to reach $8.6 billion by 2016 at a compound annual growth rate
(CAGR) of 12.5% for the five year period of 2011 to 2016.
The overall emerging markets for therapeutic drugs totaled $131.4 billion in
2009. These regions include Latin America, China, Eastern Europe, the Middle
East, South Korea, India, Russia, and South Africa. These regions are
estimated at $145.8 billion in 2010 and expected to continue aggressive growth
through 2015, reaching a figure of $214.2 billion, yielding a compound annual
growth rate (CAGR) of 8% from 2010 to 2015.
The global market for blood-brain barrier (BBB) technology for therapeutics
amounted to $12.3 million in 2010 and will reach $387 million by 2015, a
compound annual growth rate (CAGR) of 99.3%.
REPORT SCOPE
FOREWARD
The pharmaceutical industry continues to twist and turn toward the sunlight,
and away from the darkness of the patent cliff. As growth rates slow, alarm
is never far from the lips. Purchasing power within middle-income families in
BRIC countries (Brazil, Russia, India, and China) is often described as being
just what the doctor ordered, but in truth " blockbuster" means something far
smaller here, while affordability and IP issues become more pressing.
Some companies pursue new classes of therapy by exploring ways to enter the
blood brain barrier with specialized formulations or procedures, which may
reawaken the concept of lifestyle drugs. Others keep the light burning by
looking for ways to deliver RNAi and stem cell therapies. Still others dredge
the vast oceans for novel chemical entities. Ultimately, innovation is the
only sure cure for stalled sales.
BCC Research has provided comprehensive coverage of pharmaceutical markets for
many years, and we are now increasing our coverage of global pharmaceutical
markets. This review of pharmaceutical market research conducted in 2011 is
meant to provide a sampling of the type of quantitative market information,
analysis and guidance that has been aiding business decision-making since BCC
was founded in 1971.
This review includes highlights from the following reports on pharmaceutical
markets published BCC Research:
- Global Markets for Marine-Derived Pharmaceuticals
- Emerging Regional Markets for Therapeutic Drugs
- Blood-Brain Barrier Technologies and Global Markets
- Drugs for Treating Mental Disorders: Technologies and Global Markets
- Generic Drugs: The Global Market
- Vaccine Technologies and Global Markets
- The Clinical Trials Business
We hope you find this Research Review valuable, and we look forward to serving
our customers' pharmaceutical market research needs.
Chris Spivey
Senior Editor
BCC Research
Table of Contents
Chapter- 1: 2011 PHARMACEUTICALS RESEARCH REVIEW - Complimentary
Chapter- 2: GLOBAL MARKETS FOR MARINE-DERIVED PHARMACEUTICALS (PHM101A)
- INTRODUCTION
- EXECUTIVE SUMMARY
- INVESTMENT AND PATH FORWARD
- KEY DRIVERS
- KEY CHALLENGES
- KEY TRENDS
- INVESTMENT LANDSCAPE
- OVERVIEW
Chapter- 3: EMERGING REGIONAL MARKETS FOR THERAPEUTIC DRUGS (PHM076A)
- INTRODUCTION
- SUMMARY
- OVERVIEW
- Table 5 : ECONOMIC STATISTICS AND GROSS DOMESTIC PRODUCTION FOR EMERGING
COUNTRIES, 2008
Chapter- 4: BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS (PHM075A)
- INTRODUCTION
- EXECUTIVE SUMMARY
- EMERGING BBB TECHNOLOGY MARKET
- KEY DRIVERS
- KEY CHALLENGES
- MAJOR TRENDS
- OVERVIEW
- TODAY'S PHARMA MARKET
- BIOLOGICS
- GENERICS SIGNAL NEED FOR INNOVATION
- NEUROFOCUSING IN THE PHARMA INDUSTRY
- EMERGING BBB TECHNOLOGY MARKET
- BRIEF HISTORY OF BBB
- BLOOD BRAIN BARRIER DEFINED
- BBB COMPONENTS
- BBB ILLUSTRATED
- MAIN AREAS OF THE BRAIN
- TREATING DISEASE AND THE BBB
- BBB TECHNOLOGY CLASSIFICATION
- MOST COMMON BBB TECHNOLOGY
- TRANSPORT CONSIDERATIONS
- BBB TECHNOLOGY DETAILED
- ENHANCING BIOLOGICAL TRANSPORT SYSTEM TECHNIQUES
- NANOPARTICLES AND LIPOSOMES
Chapter- 5: DRUGS FOR TREATING MENTAL DISORDERS: TECHNOLOGIES AND GLOBAL MARKETS (PHM074A)
- INTRODUCTION
- SUMMARY
- INTRODUCTION
- DRIVERS AND CHALLENGES OF THE MENTAL HEALTH PHARMACEUTICAL MARKET
- MENTAL HEALTH ORGANIZATIONS
- GENERAL OVERVIEW OF THE MENTAL HEALTH PHARMACEUTICAL MARKET
- DIAGNOSTICS FOR MENTAL ILLNESSES
- PSYCHOTHERAPY FOR THE TREATMENT OF MENTAL DISORDERS
- Table 16 : U.S. PSYCHOTHERAPY TREATMENT STATISTICS, 2009
Chapter- 6: GENERIC DRUGS: THE GLOBAL MARKET (PHM009F)
- INTRODUCTION
- SUMMARY
- MARKET SIZE AND EVOLUTION
- OVERVIEW
- RECENT HISTORY OF THE GENERICS SECTOR
- THE NEW GENERICS ERA
- THE PATENT CLIFF
- TYPES OF GENERICS
Chapter- 7: VACCINE TECHNOLOGIES AND GLOBAL MARKETS (PHM014D)
- INTRODUCTION
- EXECUTIVE SUMMARY
- INDUSTRY STRUCTURE
Chapter- 8: THE CLINICAL TRIALS BUSINESS (PHM027C)
- INTRODUCTION
- SUMMARY
- OVERVIEW
- TYPES OF CLINICAL TRIALS
- CLINICAL TRIAL PHASES
- WHO SPONSORS CLINICAL TRIALS?
- PHASE I
- PHASE II
- PHASE III
- PHASE IV/POST-MARKETING TRIALS
- FACTORS AFFECTING STUDY SIZE
- PHYSICIAN AND PATIENT RECRUITMENT
- U.S. GOVERNMENT REGULATIONS
List of Tables
- Table 1 : GLOBAL FORECAST FOR MARINE-DERIVED DRUGS BY TYPE, THROUGH 2016
- Table 2 : KEY DATES IN MARINE-DERIVED DRUG HISTORY
- Table 3 : GROWTH IN THE INTEREST IN MARINE NATURAL PRODUCTS BASED ON THE
NUMBER OF PRODUCTS DESCRIBED IN SCIENTIFIC JOURNALS, 1999 - 2004
- Table 4 : TOTAL EMERGING GEOGRAPHIC MARKETS BY REGION, THROUGH 2015
- Table 5 : ECONOMIC STATISTICS AND GROSS DOMESTIC PRODUCTION FOR EMERGING
COUNTRIES, 2008
- Table 6 : GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2015
- Table 7 : TOP PHARMA COMPANIES BY REVENUE, 2009
- Table 8 : DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB TECHNOLOGY
- Table 9 : GLOBAL MENTAL HEALTH PHARMACEUTICAL INDUSTRY BY DRUG CATEGORY,
THROUGH 2015
- Table 10 : GLOBAL MENTAL HEALTH PHARMACEUTICAL MARKET SHARES BY DRUG
CATEGORY, 2010
- Table 11 : U.S. LIFETIME PREVALENCE OF MENTAL HEALTH DISORDERS BY TYPE OF
ILLNESS, 2009
- Table 12 : GENETIC FACTORS ASSOCIATED WITH MENTAL HEALTH DISORDERS AND
CURRENT DIAGNOSTIC TESTS
- Table 13 : RISK OF DEVELOPING BIPOLAR DISORDER BASED ON FAMILIAL
RELATIONSHIP
- Table 14 : U.S. STATISTICAL RISK OF DEVELOPING SCHIZOPHRENIA BASED ON
FAMILIAL RELATIONSHIP
- Table 15 : GLOBAL MARKET FORECAST FOR BIOMARKERS FOR CNS DISORDERS AND
DIAGNOSTICS TESTS, THROUGH 2015
- Table 16 : U.S. PSYCHOTHERAPY TREATMENT STATISTICS, 2009
- Table 17 : MAJOR GENERICS MARKETS, THROUGH 2016
- Table 18 : GLOBAL PHARMACEUTICAL AND GENERICS MARKETS, THROUGH 2016
- Table 19 : FIRST PATENT EXPIRIES, 2012 - 2023
- Table 20 : BIOLOGICS FACING THE LAUNCH OF BIOSIMILARS, 2001 - 2006
- Table 21 : GLOBAL REVENUE OF HUMAN AND ANIMAL VACCINES, THROUGH 2015
- Table 22 : WORLD HEALTH ORGANIZATION (WHO)-PREQUALIFIED
MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES, 2010
- Table 23 : LEADING MANUFACTURERS/SUPPLIERS OF ATTENUATED (LIVE) VACCINES
- Table 24 : LEADING MANUFACTURERS/SUPPLIERS OF INACTIVATED (KILLED) VACCINES
- Table 25 : LEADING MANUFACTURERS/SUPPLIERS OF CONJUGATE VACCINES
- Table 26 : LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT/ RECOMBINANT DNA
(RDNA) VACCINES
- Table 27 : LEADING MANUFACTURERS/SUPPLIERS OF SUBUNIT VACCINES
- Table 28 : LEADING MANUFACTURERS/SUPPLIERS OF TOXOID VACCINES
- Table 29 : LEADING MANUFACTURERS/SUPPLIERS OF COMBINATION VACCINES
- Table 30 : GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ATTENUATED
(LIVE) VACCINES, 2009
- Table 31 : GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INACTIVATED
(KILLED) VACCINES, 2009
- Table 32 : GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF CONJUGATE
VACCINES, 2009
- Table 33 : GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF
RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, 2009
- Table 34 : GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUBUNIT
VACCINES, 2009
- Table 35 : GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF TOXOID
VACCINES, 2009
- Table 36 : GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF COMBINATION
VACCINES, 2009
- Table 37 : U.S. FORECAST OF SPONSORED CLINICAL TRIALS MARKET, THROUGH 2014
- Table 38 : U.S. FORECAST OF SPONSORED CLINICAL TRIALS, THROUGH 2014
- Table 39 : PHASES OF THE CLINICAL TRIAL
- Table 40 : U.S. LAWS AFFECTING DRUG APPROVAL TIMES
- Table 41 : TOTAL APPROVED ACTIVE MOIETIES WITH NO MARKETING PROTECTION FOR
WHICH FDA HAS ISSUED A WRITTEN REQUEST
- Table 42 : CDER APPROVAL TIMES FOR PRIORITY AND STANDARD NDAS AND BLAS,
CALENDAR YEARS, 1993 - 2008
- Table 43 : FIRST CYCLE APPROVAL RATE FOR OVERALL STUDY COHORT BY YEAR,
2002 - 2007
- Table 44 : NUMBER AND TOTAL APPROVAL TIME (IN MONTHS) OF APPROVED NDAS AND
BLAS BY FISCAL YEAR OF SUBMISSION AND BY REVIEW PROCEDURE
- Table 45 : INSURANCE COMPANIES OFFERING CLINICAL TRIAL LIABILITY INSURANCE
List of Figures
- Figure 1 : GLOBAL FORECAST FOR MARINE-DERIVED DRUGS, 2010 - 2016
- Figure 2 : THE TUNICATE ECTEINASCIDIA TURBINATE FROM WHICH YONDELIS
(TRABECTEDIN) FOR CANCER TREATMENT IS MADE
- Figure 3 : MARINE SPECIES PER PHYLUM BASED ON WORMS
- Figure 4 : APPROXIMATION OF KNOWN VERSUS POSSIBLE SPECIES WITHIN THREE
PHYLA, 2011
- Figure 5 : TOTAL EMERGING GEOGRAPHIC MARKETS, BY REGION, 2007 - 2015
- Figure 6 : GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2015
- Figure 7 : GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS BY REGION, 2009
AND 2015
- Figure 8 : EMERGING MARKETS' GROWTH IN PHARMACEUTICAL SALES, 2015
- Figure 9 : GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS BY REGION,
2015
- Figure 10 : INVESTMENT IN BIOLOGICS AS A PERCENTAGE OF TOTAL R&D, 2009
- Figure 11 : CNS REVENUE DISTRIBUTION BY DISEASE TARGET, 2009
- Figure 12 : GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, 2015 AND
2017
- Figure 13 : GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS BY
INDICATION, 2015 AND 2017
- Figure 14 : PARTS OF THE BBB
- Figure 15 : THE BRAIN: BBB PROTECTS AND BRIDGES IT TO BLOOD VESSELS
- Figure 16 : METHODS OF CROSSING THE BBB
- Figure 17 : GLOBAL MENTAL HEALTH PHARMACEUTICAL INDUSTRY BY DRUG CATEGORY,
2009 - 2015
- Figure 18 : GLOBAL MENTAL HEALTH PHARMACEUTICAL MARKET SHARES BY DRUG
CATEGORY, 2010
- Figure 19 : MAJOR GENERICS MARKETS, THROUGH 2016
- Figure 20 : GLOBAL REVENUE OF HUMAN AND ANIMAL VACCINES, 2008 - 2015
- Figure 21 : GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ATTENUATED
(LIVE) VACCINES, 2009
- Figure 22 : GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INACTIVATED
(KILLED) VACCINES, 2009
- Figure 23 : GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF CONJUGATE
VACCINES, 2009
- Figure 24 : GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF
RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, 2009
- Figure 25 : GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF SUBUNIT
VACCINES, 2009
- Figure 26 : GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF TOXOID
VACCINES, 2009
- Figure 27 : GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF COMBINATION
VACCINES, 2009
- Figure 28 : U.S. FORECAST OF SPONSORED CLINICAL TRIALS MARKET, 2009 - 2014
- Figure 29 : U.S. SPONSORED CLINICAL TRIALS MARKET, 2009 - 2014
- Figure 30 : DRUG DEVELOPMENT TIME LINE
- Figure 31 : NEW DRUG DEVELOPMENT
|
